Eris Lifesciences Limited (ERIS.NS)
INR 1401.3
(0.86%)
INR 1401.3
(0.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 6.98 Billion INR | 23.17% |
| 2022 | 5.48 Billion INR | 10.28% |
| 2021 | 5.11 Billion INR | 14.39% |
| 2020 | 4.39 Billion INR | 14.63% |
| 2019 | 3.83 Billion INR | 8.26% |
| 2018 | 3.76 Billion INR | 7.91% |
| 2017 | 3.47 Billion INR | 20.08% |
| 2016 | 2.93 Billion INR | 56.98% |
| 2015 | 1.67 Billion INR | 41.45% |
| 2014 | 1.24 Billion INR | 22.63% |
| 2013 | 1.03 Billion INR | 8.79% |
| 2012 | 873.36 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 2.49 Billion INR | 53.83% |
| 2024 Q2 | 2.69 Billion INR | 6.93% |
| 2023 Q4 | 1.48 Billion INR | -17.4% |
| 2023 Q1 | 1.7 Billion INR | 42.4% |
| 2023 Q3 | 1.79 Billion INR | -2.66% |
| 2023 FY | - INR | 23.17% |
| 2023 Q2 | 1.84 Billion INR | 8.14% |
| 2022 Q3 | 1.39 Billion INR | -10.97% |
| 2022 Q4 | 1.19 Billion INR | -14.01% |
| 2022 Q1 | 1.31 Billion INR | 25.71% |
| 2022 FY | - INR | 10.28% |
| 2022 Q2 | 1.56 Billion INR | 18.7% |
| 2021 Q2 | 1.46 Billion INR | 10.9% |
| 2021 Q4 | 1.04 Billion INR | -17.29% |
| 2021 FY | - INR | 14.39% |
| 2021 Q1 | 1.32 Billion INR | 36.86% |
| 2021 Q3 | 1.26 Billion INR | -13.56% |
| 2020 Q3 | 1.1 Billion INR | -13.05% |
| 2020 Q2 | 1.26 Billion INR | 20.35% |
| 2020 Q1 | 1.05 Billion INR | 38.38% |
| 2020 Q4 | 967.3 Million INR | -12.3% |
| 2020 FY | - INR | 14.63% |
| 2019 Q2 | 1.15 Billion INR | 7.15% |
| 2019 FY | - INR | 8.26% |
| 2019 Q3 | 852.47 Million INR | -25.88% |
| 2019 Q4 | 761.68 Million INR | -10.65% |
| 2019 Q1 | 1.07 Billion INR | 45.29% |
| 2018 Q1 | 920.75 Million INR | 16.5% |
| 2018 Q4 | 738.8 Million INR | -28.83% |
| 2018 FY | - INR | 7.91% |
| 2018 Q2 | 1.06 Billion INR | 16.04% |
| 2018 Q3 | 1.03 Billion INR | -2.84% |
| 2017 FY | - INR | 20.08% |
| 2017 Q4 | 790.33 Million INR | -9.03% |
| 2017 Q1 | 783.04 Million INR | 63.57% |
| 2017 Q2 | 1.04 Billion INR | 33.08% |
| 2017 Q3 | 868.74 Million INR | -16.64% |
| 2016 Q1 | 787.46 Million INR | 0.0% |
| 2016 Q3 | 780.87 Million INR | -5.97% |
| 2016 FY | - INR | 56.98% |
| 2016 Q4 | 478.71 Million INR | -38.7% |
| 2016 Q2 | 830.49 Million INR | 5.46% |
| 2015 FY | - INR | 41.45% |
| 2014 FY | - INR | 22.63% |
| 2013 FY | - INR | 8.79% |
| 2012 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Sigachi Industries Limited | 883.39 Million INR | -690.861% |
| Ind-Swift Limited | 1.06 Billion INR | -555.964% |
| Bajaj HealthCare Limited | 406.23 Million INR | -1619.792% |
| Sakar Healthcare Limited | 393.26 Million INR | -1676.511% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 88.693% |
| Innova Captab Limited | 1.66 Billion INR | -318.774% |
| Divi's Laboratories Limited | 25.43 Billion INR | 72.527% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -196.438% |
| Morepen Laboratories Limited | 1.72 Billion INR | -304.788% |
| Mankind Pharma Limited | 28.09 Billion INR | 75.132% |
| Sequent Scientific Limited | 549.8 Million INR | -1170.726% |
| Wanbury Limited | 985.49 Million INR | -608.932% |
| Laurus Labs Limited | 8 Billion INR | 12.735% |
| Nectar Lifesciences Limited | 1.53 Billion INR | -354.968% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | -1.801% |
| Alembic Limited | 1.11 Billion INR | -525.835% |
| Hikal Limited | 2.69 Billion INR | -159.504% |
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 27.351% |
| Neuland Laboratories Limited | 4.74 Billion INR | -47.139% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 25.157% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 38.411% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -168.029% |
| Themis Medicare Limited | 562.6 Million INR | -1141.799% |
| RPG Life Sciences Limited | 1.28 Billion INR | -445.178% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 87.573% |
| Lupin Limited | 36.96 Billion INR | 81.102% |
| Amrutanjan Health Care Limited | 681.59 Million INR | -925.013% |
| Wockhardt Limited | 1.08 Billion INR | -546.894% |
| Vaishali Pharma Limited | 31.71 Million INR | -21931.629% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | -78.708% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -2059.912% |
| Jubilant Pharmova Limited | 8 Billion INR | 12.735% |
| FDC Limited | 3.38 Billion INR | -106.372% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 92.086% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -2330.704% |
| Venus Remedies Limited | 711.8 Million INR | -881.517% |
| ZIM Laboratories Limited | 462.09 Million INR | -1411.901% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -372.367% |
| Par Drugs and Chemicals Limited | 228.17 Million INR | -2961.896% |
| Caplin Point Laboratories Limited | 6.18 Billion INR | -12.98% |
| Shilpa Medicare Limited | 2.58 Billion INR | -169.957% |
| Albert David Limited | 1.04 Billion INR | -568.289% |
| Ajanta Pharma Limited | 12.56 Billion INR | 44.399% |
| Hester Biosciences Limited | 539.47 Million INR | -1195.058% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | -49.373% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 347.58% |
| Gufic Biosciences Limited | 1.48 Billion INR | -371.902% |
| Windlas Biotech Limited | 781.72 Million INR | -793.728% |
| Procter & Gamble Health Limited | 3.07 Billion INR | -127.246% |
| Aarey Drugs & Pharmaceuticals Limited | 45.16 Million INR | -15368.726% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -3893.489% |
| Granules India Limited | 8.6 Billion INR | 18.798% |
| Aarti Drugs Limited | 3.24 Billion INR | -115.058% |
| Bal Pharma Limited | 345.59 Million INR | -1921.589% |
| Alkem Laboratories Limited | 24.19 Billion INR | 71.125% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 94.951% |
| Lincoln Pharmaceuticals Limited | 1.34 Billion INR | -420.088% |
| Medicamen Biotech Limited | 245.66 Million INR | -2743.951% |
| Unichem Laboratories Limited | 742.35 Million INR | -841.119% |
| Bafna Pharmaceuticals Limited | 114.58 Million INR | -5997.283% |
| Biofil Chemicals and Pharmaceuticals Limited | 12.99 Million INR | -53658.464% |
| Valiant Laboratories Limited | 12.73 Million INR | -54743.002% |
| Orchid Pharma Limited | 1.41 Billion INR | -392.288% |
| Medico Remedies Limited | 129.09 Million INR | -5311.909% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | -1.819% |
| Ipca Laboratories Limited | 13.29 Billion INR | 47.468% |
| Brooks Laboratories Limited | 41.72 Million INR | -16642.835% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -1523.714% |
| Piramal Enterprises Limited | -3.86 Billion INR | 280.945% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 80.044% |
| NATCO Pharma Limited | 18.79 Billion INR | 62.828% |
| Suven Life Sciences Limited | -992.78 Million INR | 803.726% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 8545.187% |
| Strides Pharma Science Limited | 3.76 Billion INR | -85.579% |
| Indoco Remedies Limited | 2.64 Billion INR | -163.933% |
| Alpa Laboratories Limited | 229.96 Million INR | -2938.102% |
| Lasa Supergenerics Limited | -65.08 Million INR | 10835.172% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 287.231% |